Navigation Links
Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
Date:10/8/2007

LONDON, Oct. 9 /PRNewswire/ -- Chiltern, a leading global clinical research organization, has announced the appointment of Steve Albrecht to the role of Director, Business Operations, Late Phase. Steve Albrecht brings over 20 years of CRO industry experience to his new appointment; previously he held executive management positions with other major CROs and recently Registrat in late phase development.

Mr. Albrecht will be providing leadership for the development, implementation and execution of Chiltern's Late Phase strategies.

"I am delighted to join the current excellent staff at Chiltern," said Steve "and I look forward to further developing the Late Phase division in order to provide our sponsors with the best available options for the conduct of their Phase IIIb/IV studies. Post marketing studies pose an excellent opportunity to combine the knowledge gained in early phase development with well-designed and implemented late phase programs. Today, FDA and the pharmaceutical industry are mandating an ever-increasing number of post-marketing trials to follow products in a real-world setting. These studies require high quality standards yielding high quality data."

"I am delighted that Steve has joined Chiltern," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "Steve's strong background in Late Phase will add strength to our group and provide sponsors with services in the design and execution of both commercial programs and risk management programs for their marketed products."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier Richard Baptista

Chiltern International, Inc. Chiltern International Ltd.

2111 Palomar Airport Road 171 Bath Road

Suite 200 Slough

Carlsbad Berkshire

CA 92011 SL1 4AA

USA UNITED KINGDOM

Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000

Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116

Email: Catherine.Lemercier@chiltern.com Email:

Richard.Baptista@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Steve Tyler Tells All About His Beauty Regime
2. Prince Charles lends support to Alternative Medicine
3. Support therapy helps breast cancer patients
4. Evidence supporting H.pylori eradication
5. Further support for use of statins in Alzheimer’s disease
6. Toxin injections support stroke associated spasticity
7. Support for patients with Leg Pain
8. Vitamin E supports Female Hearts
9. Injection supports Heart Devices
10. Modified antibiotic may support fight cancer
11. WHO To Support Public Health Threats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 26, 2016 ... value-based care operating models within the health care industry ... greater financial efficiency , Deloitte offers a suite ... key business issues impacting efficient cost optimization: labor resource ... , These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
Breaking Medicine Technology: